Memorandum

Subject	Date
Additional Quota Letters Received by July 15, 2010 (DFN: 630-08.2)	JUL 16 2010

To

Christine A. Sannerud. Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On July 15. 2010, this section received your e-mail requesting a review of seventeen (17) quota applications from sixteen (16) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Novartis Consumer Health Lincoln (10345)
Baxter (10346)
Generics Bidco II bda Vintage (10347)
Noramco Delaware (10348)
Pharmaceuticals International Inc. (10349)
Pharmedium (10351)
Pharmedium (10352)
Rhodes (10356)
Bio-Pharm (10357)
Patheon (10358)
Patheon (10359)
Watson (10361)
B & B (10363)
Hospira. Inc. NC (10364)
Epic Pharma (10366)
Mallinckrodt Hobart (10367)
Chemtos (10368)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject	Date
Additional Quota Letters Received as of July 19, 2010 (DFN: 630-08.2)	JUL 2 8 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On July 19, 2010, this section received your e-mail requesting a review of six (06) quota applications to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Sigma Aldrich (10370)
Emerson (10372)
Watson (10373)
Catalent (10374)
Akorn dba Taylor (10375)
Akorn dba Taylor (10376)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(7)(E)

Memorandum

Subject	Date
Additional Quota Letters as of July 30, 2010 (DFN: 630-08.2)	AUG 2 5 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On July 30, 2010, this section received your e-mail requesting a review of forty-five (45) quota applications from twenty-four (24) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc). as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

DSM (10378)
Siegfried (10380)
Chemtos (10381)
Fisher Virginia (10382)
Fisher Virginia (10383)
Fisher Virginia (10384)
Cambrex (10385)
Purdue North Carolina (10385)
Purdue North Carolina (10387)
AustarPharma (10390)
AustarPharma (10391)
Letco Medical (10392)
Noramco Georgia (10393)
Johnson Matthey (10394)
Johnson Matthey (10395)
Johnson Matthey (10396)
Johnson Matthey (10397)
Johnson Matthey (10398)
Johnson Matthey (10399)
Johnson Matthey (10400)

(b)(4);(b)(7)(E)

Johnson Matthey (10402)
Johnson Matthey (10403)
Johnson Matthey (10404)
Johnson Matthey (10405)
AAI (10406)
Barr Virginia (10407)
Noramco Delaware (10408)
DSM (10409)
Mallinckrodt St. Louis (10411)
Janssen Cilag (10412)
Almac (10413)
Mallinckrodt St. Louis (10414)
Alza Vacaville (10416)
Johnson Matthey (10417)
Hospira, Inc NC (10418)
DSM (10419)
Cambrex (10420)
Barr (10421)
Noramco (10424)
Noramco (10425)
Noramco (10426)
Bilcare (10427)
Mallinckrodt St. Louis (10428)
Halo (10429)
Siegfried (10430)

(b)(4);(b)(7)(E)

Per consultation with the field office, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject	Date
Additional Quota Letters Received as of August 16, 2010 (DFN: 630-08.2)	SEP 01 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On August 16, 2010, this section received your e-mail requesting a review of forty-five (45) quota applications from thirty-eight (38) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

CorePharma Wood Ave (10434)
Noramco Georgia (10437)
Elan Holdings (10439)
Roxane Oak Street (10440)
Bilcare Global Clinical Supplies (10441)
Vintage Generics Bidco (10443)
Noramco Delaware (10444)(1 of 2)
Micron Twchnologies, Inc ((10444)(2 of 2)
Fisher Virginia ((10445)
Hospira Inc KS (10446)
Boehringer Ingelheim (10447)
Purdue North Carolina (10448)
Amneal - Brookhaven (10449)
Med-Pharmex (10452)
Janssen Puerto Rico (10453)
AMRI (10454)
PCCA (10455)
Patheon (10456)
Noramco Delaware (10457)
Aptuit (10458)

(b)(4);(b)(7)(E)

Norwich (10459)
Catalent Pharma Solutions (10468)
Watson New Jersey (10469) (1 of 2)
Watson New Jersey (10469) (1 of 2)
Hisamitsu California Laboratories (10470)
Hisamitsu California Laboratories (10471)
Noramco Georgia (10472)
Fisher Pennsylvania (10473)
Amneal – Brookhaven (10474)
Watson Laboratories, Inc (10478) (1 of 2)
Watson Laboratories, Inc (10478) (2 of 2)
Sun New Jersey (10479)
DSM (10480) (1 of 2)
DSM (10480 (2 of 2)
Cambrex (10482)
UCB Manufacturing (formerly Celltech NY) (10483)
Palmetto State Pharmaceuticals (10485)
Ortho McNeil Pharmaceutical (10486)
Bilcare (10487)
Noramco Delaware (10488)
Pii (10489) (1 of 2)
Pii (10489) (2 of 2)
Catalent Pharma Solutions (19456)

(b)(4);(b)(7)(E)

QUOTA APPLICANTS WITH ADVERSE OR DEROGATORY INFORMATION

(b)(4);(b)(7)(E)

Currently Under Review/Investigation

Per consultation with the field office, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject	Date
Additional Quota Letters Received as of August 26, 2010 (DFN: 630-08.2)	SEP 01 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On August 26, 2010, this section received your e-mail requesting a review of forty-one (41) quota applications from thirty-two (32) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Johnson Matthey (10491)
Corium (10492)
Novartis (10493)
DPT Paco Way (10494)
United Liquid, Inc. (10495)
King Pharmaceuticals (10496)
Barr Virginia (10497)
ANI Pharmaceuticals, Inc (10498)
AustarPharma (10499) (1 0f 2)
AustarPharma (10499) (2 of 2)
Cima Brooklyn Park (10501)
Cima Brooklyn Park (10502)
Noramco Delaware (10503)
King (10504)
Barr Virginia (10505)
Sun New Jersey (10506)
Novartis Consumer Health Lincoln (10507)
Diamond Animal (10508)
Fisher Pennsylvania (10509)
Cerilliant (10510)

(b)(4);(b)(7)(E)

Pharmaceutics International (10511)
Chattem (10512)
Boehringer Ingelheim (10513)
Barr Virginia (10514)
Unique Pharmaceuticals (10515)
King (10517)
Mallinckrodt St. Louis (10518)
Ohm (10519)
Norac, Inc. (10521)
Nucare Pharmaceuticals (10522)
Ohm (10529)
Watson Pharmaceuticals (10530) (1 of 2)
Watson Pharmaceuticals (10530) (2 of 2)
Patheon (10531)
Watson Pharmaceuticals (10534) (1 of 2)
Watson Pharmaceuticals (10534) (2 of 2)
Watson Pharmaceuticals (10535) (1 of 2)
Watson Pharmaceuticals (10535) (2 of 2)
Impax Pennsylvania (10536)
Purdue North Carolina (10537)
Aurolife Pharma (10538)

(b)(4);(b)(7)(E)

Per consultation with the field office, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject	Date
Additional Quota Letters Received as of September 13, 2010 (DFN: 630-08.2)	SEP 2 9 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On September 13, 2010, this section received your e-mail requesting a review of forty-eight (48) quota applications from thirty-eight (38) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Great Southern (10540)
Tris Pharma, Inc. (10541)
Mallinckrodt St. Louis (10542)
Mallinckrodt St. Louis (10543)
VistaPharm (10544)
Ameridose, LLC (10547)
Metrics (10549)
Central Admixture – San Diego (10552)
Central Admixture - San Diego (10553)
Siegfried (10554)
Mallinckrodt (10555)
Mallinckrodt (10556)
Noramco Delaware (10558)
Mallinckrodt St. Louis (10559)
Purdue North Carolina (10560)
Mylan Chestnut Ridge Road, West Virginia (10561)
Cedarburg (10562)
Hospira, Inc. (10563)
PCCA (10564)
Southwest Research Institute (10565)

(b)(4);(b)(7)(E)

Vintage Pharmaceuticals (10566)
Vintage Pharmaceuticals (10567)
Tedor Pharma Inc. (10569)
Mallinckrodt (10571)
Corium (10572)
KV Pharmaceutical (10573)
KV Pharmaceutical (10573)(2 of 3)
KV Pharmaceutical (10573)(3 of 3)
Chemtos (10574)
Gallipot, Inc. (10575)
Lannett Co., Inc. (10576)
Epic Pharma, LLC (10577)
Archimica (10578)
Mylan (10579)
Boehringer Ingelheim (10580)
B&B Pharmaceuticals (10582)
B&B Pharmaceuticals (10583)
Barr Laboratories (10584)
Barr Laboratories (10585)
Ohm (10586)
Hospira, Inc. (10587)
Actavis Elizabeth (10588)
AMRI (10590)
AMRI (10591)
Boehringer Ingelheim (10592)
Siegfried (10594)
King (10595)
Schwarz (10597)

(b)(4);(b)(7)(E)

Per consultation with the field office, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject	Date
Additional Quota Letters Received as of September 21, 2010 (DFN: 630-08.2)	SEP 2 9 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

for James Arnold
Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On September 21, 2010, this section received your e-mail requesting a review of thirty-two (32) quota applications from twenty-eight (28) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Noramco, Inc (10600)
Nexgen Pharma, Inc (10601)
Bend Research, Inc (10603)
ANI Pharmaceuticals, Inc (10604)
Generics Bidco II (10605)
Vintage Pharmaceuticals (10606)
Metrics (10607)
Catalent Pharma Solutions (10608)
PCCA (10609)
Halo Pharmaceutical (10610)
Novartis Consumer Health Lincoln (10611)
Bilcare (10612)
Norwich Pharmaceuticals (10617)
Austar Pharma LLC (10618)
Ohm Laboratories (10619)
Fisher Clinical Services (10620)
Fisher Clinical Services (10621)
Nexgen Pharma, Inc (10622)
Hospira, Inc (10623)
Covidien (10624)

(b)(4);(b)(7)(E)

PII (10625)
Hospira, Inc (10631)
Fisher Clinical Services (10632)
Fisher Clinical Services (10633)
Fisher Clinical Services (10634)
Coating Place Inc (10635)
Cerilliant (10636)
Epic Pharma (10637)
Siegfried (10638)
Patheon (10639)
Watson Connecticut (10640)
Mylan Pharmaceuticals (10641)

(b)(4);(b)(7)(E)

Per consultation with the field office, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject	Date
Quota Letters Received as of October 4, 2010 (DFN: 630-08.2)	OCT 0 5 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

for Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On October 4, 2010, this section received your e-mail requesting a review of twenty-three (23) quota applications from twenty-one (21) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

- Pharmedium (10653)
- Pharmedium (10654)
- AustarPharma, LLC (10656)
- Janssen Cilag (10666)
- Sigma-Aldrich Research Biochemicals (10667)
- Ohm (10668)
- PCCA ((10674)
- Barr Laboratories, Inc. (10677)
- Barr Laboratories, Inc. (10678)
- Shire (10679)
- Dispensing Solutions, Inc. (10680)
- Watson Laboratories, Inc. (10681)
- Watson Laboratories, Inc. (10681)(2 of 2)
- UCB Manufacturing (formerly Celltech NY)(10682)
- Classic (10683)
- AMRI (10685)
- Noramco, Inc. (10686)
- PCCA (10687)
- Actavis South-Atlantic (10690)
- Pii (10691)

(b)(4);(b)(7)(E)

- Noramco Delaware (10692)
- Noramco Delaware (NA009) (1 of 2)
- Noramco Georgia (NA009 (2 of 2)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject	Date
Quota Letters Received as of October 8, 2010 (DFN: 630-08.2)	OCT 1 4 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On October 8, 2010, this section received your e-mail requesting a review of twenty-two (22) quota applications from twenty-one (21) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Tris Pharma, Inc. (10657)
Anazao Health (10658)
Elan Holdings (10660)
Safecor Health, LLC (Regional Service Center)(10661)
Pfizer, Inc (10662)
Aurolife Pharma LLC (10663)
AAI Pharma, Inc. (10664)
Sharp Corporation (10665)
Restek (10694)
Hospira, Inc. (10695)
Amneal - Brookhaven (10696)
Rhodes (10697)
DPT (10698)
Novartis Consumer Health Lincoln (10699)
Actavis South-Atlantic (10701)
Anazao Health (10702)
Mylan Technologies (10704)
VistaPharm (10705)
Covidien (10707)

(b)(4);(b)(7)(E)

Barr Laboratories (10708)
Noramco (10709)
Catalent (10710)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject	Date
Quota Letter Received (DFN: 630-08.2)	OCT 14 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On October 12, 2010, this section received your e-mail requesting a review of one (1) quota application from a registered manufacturer to determine if there are any pending administrative/legal actions against this applicant and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

UCB Manufacturing (formerly Celltech NY) (10682) (b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject	Date
Quota Letters Received as of October 14, 2010 (DFN: 630-08.2)	OCT 2 0 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On October 14, 2010, this section received your e-mail requesting a review of twenty-four (24) quota applications from twenty-one (21) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Halo Pharma (10718)
Fisher Clinical (10719)
Shire (10720)
DSM (10721)
Patheon (10722)
Hospira, Inc. (10723)
AAIPharma Services (10724)
Tris Pharma, Inc. (10725)
Cody Labs (10726)
Cody Labs (10727)
Coating Place Inc. (10728)
Taylor Pharmaceuticals (10729)
Restek (10730)
DSM (10731)
Patheon (10732)
Aptuit (10733)
Spectrum (10734)
Aptuit (10735)
Norac, Inc. (10739)
Sandoz (formerly Geneva Pharma) (10740)

(b)(4);(b)(7)(E)

Medisca, Inc. (10741)
TEVA (10742)
Fisher Clinical Services (10743)
Janssen Cilag (10744)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject

Initial 2010 Manufacturing Quota Letters
DFN:630-08.2

Date

OCT 2 1 2009

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

Barbara Boockholdt

Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On October 15, 2009, this section received your e-mail requesting a review of twenty-four (24) quota applications from registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc) as well as surveyed the responsible field offices for their input and advisement. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Alltech Associates
American Radiolabeled Chemicals
AMRI Rensselaer, Inc.
Archimica, Inc.
Austin Pharma, Inc.
Boehringer Ingelheim
Cambrex Charles City, Inc.
Cayman Chemical
Cerilliant
Chattem Chemicals, Inc.
Chemtos, LLC
Halo
Johnson Matthey
Johnson Matthey Pharmaceutical Materials
Lonza
Mallinckrodt St. Louis
Norac, Inc.
Noramco Delaware
Noramco Georgia
Penick Corporation

(b)(4);(b)(7)(E)

Rhodes Technologies
Siegfried
Siemens Healthcare Diagnostics Inc.
Stephan

(b)(4);(b)(7)(E)

Per consultation with the field office, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the twenty-four (24) quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject	Date
Quota Letters Received as of October 18, 2010 (DFN: 630-08.2)	OCT 2 0 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On October 18, 2010, this section received your e-mail requesting a review of three (03) quota applications to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Covidien (10750)
Janssen Cilag (10751)
Baxter (10752)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject	Date
Quota Letters Received as of October 21, 2010 (DFN: 630-08.2)	OCT 26 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On October 21, 2010, this section received your e-mail requesting a review of twenty-three (23) quota applications from sixteen (16) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

AAI Pharma-Services (10754)
PCCA (10755)
Tris Pharma, Inc. (10756)
Covidien (10757)
Corepharma LLC (10758)
Corepharma LLC (10759)
Covidien (10761)
Covidien (10762)
Patheon (10766)
Patheon (10767)
Watson (10768)
Baxter (10769)
Epic Pharma (10770)
Cerilliant (10771)
AustarPharma (10780)
Cima Brooklyn Park (10781)
Cima Brooklyn Park (10782)
Barr Laboratories (10783)
Johnson Matthey (10784)
Colorcon (10785)

(b)(4);(b)(7)(E)

AAI Pharma Services (10786)
Covidien (10787)
Covidien (10788)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject	Date
Quota Letters Received as of October 28, 2010 (DFN: 630-08.2)	OCT 2 9 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

for James Arnold
Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On October 28, 2010, this section received your e-mail requesting a review of twelve (12) quota applications to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

(b)(4);(b)(7)(E)

Ameridose, LLC (10794) (1 of 2)
Ameridose, LLC (10794) (2 0f 2)
Archimica (10795)
Bio-Pharma (10799)
Cambrex (10792)
Cerilliant (10791)
Covidien (10793)
Johnson Matthey (10790)
PharmaForm (10796)
Rhodes (10797)
Sandoz (formerly Geneva Pharmaceuticals, Inc) (10798)
VistaPharm (10789)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject	Date
Quota Letters Received as of November 1, 2010 (DFN: 630-08.2)	NOV 0 5 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

Barbara J. Boochholdt, Chief
Regulatory Section
Office of Diversion Control

On November 1, 2010, this section received your e-mail requesting a review of nine (09) quota applications to determine if there were any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Metrics (10800)
Taylor Pharmaceuticals (10801)
AAI Pharma Services (10802)
AustarPharma (10803)
Bio-Pharm (10804)
Halo Pharma (10806)
Mikart (10807)
Mikart (10807) (2 of 2)
Vortech (10809)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject	Date
Quota Letters Received as of November 8, 2010 (DFN: 630-08.2)	NOV 0 9 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

for Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On November 8, 2010, this section received your e-mail requesting a review of ten (10) quota applications to determine if there were any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Sun Pharmaceuticals (10672)
Formurex (10738)
Janssen Cilag (10751)(1 of 2)
Elan Holdings (10817)
Noramco (10819)
Pii (10820)
Medisca (10821)
Tris Pharma, Inc. (10822)
Novartis Consumer Health Lincoln (10824)
Covidien (10832)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject	Date
(b)(4);(b)(7)(E) 2010 Procurement Quota Increase Request Hydrocodone (DFN:630-08.2)	NOV 0 9 2010

To

Christine A. Sannerud, Ph.D, Chief
Drug & Chemical Evaluation Section
Office of Diversion Control

From

for Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On November 5, 2010, this section received your memorandum requesting a review of the (b)(4) customers list, specifically, information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order.

ODGR conducted NADDIS and CSA reviews of approximately one hundred sixty-eight (168) of (b)(4) customers as well as on (b)(4)

The following derogatory information was found on the seven (7) below listed customers:

(b)(4);(b)(7)(E)	**Retired 05/21/2010** **Currently Under Review/Investigation** **Currently Under Order to Show Cause** **Currently Under Review/Investigation** **Currently Under Review/Investigation** **Currently Under Review/Investigation** **Currently Under Review/Investigation** **Currently Under Review/Investigation**

DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the request submitted by (b)(4) for the quota increase.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject	Date
Quota Letters Received as of November 12, 2010 (DFN: 630-08.2)	NOV 1 6 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

for Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On November 12, 2010, this section received your e-mail requesting a review of seven (07) quota applications to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Nexgen Pharma, Inc (10811)
Watson (10812)
Boehringer Ingelheim (10816)
Johnson Matthey (10834)
Novartis Consumer Health Lincoln (10835)
AMRI (10836)
Catalent (10837)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject	Date
Quota Letters Received as of November 18, 2010 (DFN: 630-08.2)	NOV 1 9 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

for Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On November 18, 2010, this section received your e-mail requesting a review of nineteen (19) quota applications from eighteen (18) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Aptuit, Inc. (10735s)
Elan Holdings (10749)
Novartis (10808)
Watson (10845)
Novartis (10846)
Par Pharmaceutical (10847)
Rhodes Technologies (10849)
Barr Laboratories (10850)
CoreRx Inc. (10851)
AustarPharma (10852)
Mylan Technologies (10853)
GPSG (10854)
Tedor Pharma Inc. (10855)
Covidien (10858)
KVK-Tech Inc. (10859)
Catalent Pharma Solutions (10861)
Sharp Corporation (10862)
AAI Pharma Services (10863)
AnazaoHealth (10864)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject	Date
(b)(4);(b)(7)(E) 2010 Procurement Quota Increase Request Hydrocodone (DFN:630-08.2)	NOV 1 9 2010

To

Christine A. Sannerud, Ph.D, Chief
Drug & Chemical Evaluation Section
Office of Diversion Control

From

Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On November 17, 2010, this section received your memorandum requesting a review of the (b)(4) customers list, specifically, information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order.

ODGR conducted NADDIS and CSA reviews of approximately one hundred fifty-three (153) of (b)(4) customers as well as on (b)(4)

The following derogatory information was found on the seven (7) below listed customers:

(b)(4);(b)(7)(E)	**Retired 11/17/2010** **Currently Under Review/Investigation** **Currently Under Review/Investigation** **Currently Under Review/Investigation** **Currently Under Order to Show Cause** **Currently Under Review/Investigation** **Currently Under Review/investigation**

DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the request submitted by (b)(4) for the quota increase.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject	Date
Quota Letters Received as of November 29, 2010 (DFN: 630-08.2)	NOV 3 0 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

for Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On November 29, 2010, this section received your e-mail requesting a review of seven (07) quota applications to determine if there were any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Actavis (10870)
Cody Labs (10876)
DPT (10872)
Endo Pharmaceutical (10873)
Mylan (10874)
Watson (10875)
Watson (10875) (2 of 2)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject	Date
Quota Letters Received as of December 6, 2010 (DFN: 630-08.2)	DEC 0 7 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

for Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On December 6, 2010, this section received your e-mail requesting a review of nine (09) quota applications to determine if there were any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Vintage Pharmaceuticals (10877)
Olay (10878)
Noramco Delaware (10879)
Catalent Pharma Solutions (10880)
AustarPharma (10882)
Halo Pharmaceutical Company (10885)
AAI Pharma (10886)
Safecor Health, LLC (Regional Service Center (10887)
Qualitest (10888)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject

Quota Letters Received as of Decemer 10, 2010
(DFN: 630-08.2)

Date

DEC 1 4 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

Barbara J. Boeckholdt, Chief
Regulatory Section
Office of Diversion Control

On December 10, 2010, this section received your e-mail requesting a review of five (05) quota applications to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Noramco (10892)
King Pharmaceuticals (10893)
Amneal Pharmaceuticals (10894)
Cephalon, Inc. (10895)
AAI Pharma (10899)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject	Date
Quota Letters Received as of Decemer 13, 2010 (DFN: 630-08.2)	DEC 1 4 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On December 13, 2010, this section received your e-mail requesting a review of six (06) quota applications to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Noramco (10892)
Amneal Pharmaceuticals (10894)
Cephalon, Inc. (10895)
King Pharmaceuticals (10896)
AAI Pharma (10899)
AMRI Rensselear, Inc. (10903)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject

Quota Requests as of December 14, 2010
(DFN: 630-08.2)

Date

December 20, 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On December 14, 2010, this section received your e-mail requesting a review of two-hundred and thirty-one (231) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (CSA, etc), as well as surveyed the responsible field offices as needed for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

IMQ001	Alltech Associates	(b)(4);(b)(7)(E)
IMQ002	AMRI Rensselaer	
IMQ003	Archimica	
IMQ004	Austin Pharma	
IMQ005	Cambrex	
IMQ006	Cayman Chemical	
IMQ007	Boehringer Ingelheim	
IMQ008	Cerilliant	
IMQ009	Chattem	
IMQ010	Cody	

		(b)(4);(b)(7)(E)
IMQ011	Halo Pharmaceutical Inc.	
IMQ012	Johnson Matthey	
IMQ013	Johnson Matthey Pharmaceutical Materials	
IMQ014	Johnson Matthey Pharmaceutical Materials	
IMQ015	Mallinckrodt St. Louis	
IMQ016	Norac, Inc.	
IMQ017	Noramco	
IMQ018	Noramco	
IMQ019	Penick	
IMQ020	Rhodes	
IMQ021	Siegfried	
IMQ022	Siemens Healthcare Diagnostics Inc.	
IMQ023	Stepan	
IMQ024	American Radiolabeled Chemicals	
IMQ025	Cedarburg	
IMQ026	Lonza	
IMQ027	Chemica Inc.	
IMQ028	ElSohly Laboratories, Inc.	
IPQ001	AAIPharma Services Corp.	
IPQ002	Actavis Elizabeth LLC	
IPQ003	Advanced Pharma	
IPQ004	Alltech Associates	
IPQ005	Almac Clinical Services	
IPQ006	Altea Therapeutics	
IPQ007	Arista Biologicals	

		(b)(4);(b)(7)(E)
IPQ008	B & B	
IPQ009	Banyan International Corporation	
IPQ010	Barr Laboratories, Inc.	
IPQ011	Barr Laboratories, Inc.	
IPQ012	Baxter Healthcare Corporation	
IPQ013	Biochemical Diagnostics, Inc.	
IPQ014	Bio-Rad Laboratories	
IPQ015	Biosite	
IPQ016	Boehringer Ingelheim	
IPQ017	Boehringer Ingelheim Vetmedica, Inc.	
IPQ018	Boehringer Ingelheim Roxane, Inc.	
IPQ019	Cambrex Charles City	
IPQ020	Cardinal Health	
IPQ021	Catalent Pharma Solution	
IPQ022	Catalent Pharma Solution	
IPQ023	Cephalon, Inc.	
IPQ024	Cephalon, Inc.	
IPQ025	Cephalon, Inc.	
IPQ026	Cerilliant	
IPQ027	Chattem	
IPQ028	Chemtos	
IPQ029	CIMA Labs, Inc.	
IPQ030	CIMA Labs, Inc.	
IPQ031	Classic Pharmaceuticals, LLC	
IPQ032	Cody Laboratories, Inc.	

		(b)(4);(b)(7)(E)
IPQ033	Consolidated Technologies	
IPQ034	CorePharma, LLC	
IPQ035	Dispensing Solutions, Inc.	
IPQ036	DPT Lakewood, Inc.	
IPQ037	DSM Pharmaceuticals, Inc.	
IPQ038	Elan Holdings	
IPQ039	Elge, Inc.	
IPQ040	Endo Pharmaceuticals, Inc.	
IPQ041	Epic Pharma LLC	
IPQ042	Gallipot	
IPQ043	Great Southern Laboratories	
IPQ044	Halo Pharmaceutical, Inc.	
IPQ045	Diamond Animal Health, Inc.	
IPQ046	Hi-Tech Pharmacal Co. Inc.	
IPQ047	Hospira, Inc.	
IPQ048	Hospira, Inc.	
IPQ049	Impax Laboratories, Inc.	
IPQ050	Impax Laboratories, Inc.	
IPQ051	Impax Laboratories, Inc.	
IPQ052	Abbott Laboratories North Chicago	
IPQ053	Actavis	
IPQ054	Akorn	
IPQ055	Akorn	
IPQ056	Alza Corporation	
IPQ057	Ameridose, LLC	

		(b)(4);(b)(7)(E)
IPQ058	Ameridose, LLC	
IPQ059	AstraZeneca	
IPQ060	Banner Pharmacaps	
IPQ061	BD medical	
IPQ062	Bio-Pharm	
IPQ063	Cantrell Drug Company	
IPQ064	Catalent	
IPQ065	Corium	
IPQ066	Clinical Supplies Management	
IPQ067	Elite Laboratories	
IPQ068	Generics Bidco II dba Vintage	
IPQ069	International Medication	
IPQ070	Janssen Cilag	
IPQ071	Janssen Ortho	
IPQ072	Johnson Matthey	
IPQ073	King Pharmaceuticals	
IPQ074	KV Pharmaceuticals	
IPQ075	KV Pharmaceuticals	
IPQ076	KV Pharmaceuticals	
IPQ077	Lehigh Valley Technologies, Inc.	
IPQ078	Letco Medical	
IPQ079	Mallinckrodt St. Louis	
IPQ080	Mallinckrodt Hobart	
IPQ081	Med-Pharmex	
IPQ082	Medisca	

		(b)(4);(b)(7)(E)
IPQ083	Metrics	
IPQ084	Micron Technologies, Inc.	
IPQ085	Mikart Inc.	
IPQ086	Mikart Inc.	
IPQ087	Morton Grove Pharmaceuticals, Inc.	
IPQ088	Mylan Technologies	
IPQ089	Nexgen Pharma, Inc.	
IPQ090	Noramco Delaware	
IPQ091	Noramco Georgia	
IPQ092	Norwich Pharmaceuticals	
IPQ093	Novartis	
IPQ094	Novartis	
IPQ095	Novartis Consumer Health Lincoln	
IPQ096	Novel Laboratories	
IPQ097	Noven	
IPQ098	NuCare	
IPQ099	Ohm Laboratories	
IPQ100	Ohm Laboratories	
IPQ101	Olay LLC	
IPQ102	Pacira Pharmaceuticals	
IPQ103	Pacira Pharmaceuticals	
IPQ104	Paddock Laboratories	
IPQ105	PalliRx, Inc.	
IPQ106	Patheon	
IPQ107	Penick	

		(b)(4);(b)(7)(E)
IPQ108	Pharmaceutical Associates	
IPQ109	Pharmaceutical Manufacturing Research Services, Inc.	
IPQ110	Pharmaceutics International, Inc.	
IPQ111	Pharmacia & Upjohn	
IPQ112	Pharmedium	
IPQ113	Pharmedium	
IPQ114	Physicians Total Care	
IPQ115	Purdue	
IPQ116	Purdue	
IPQ117	Quality Assurance	
IPQ118	Research Triangle Institute	
IPQ119	Restek	
IPQ120	Rhodes	
IPQ121	Roche	
IPQ122	Safecor	
IPQ123	Sandoz	
IPQ124	Schwarz Pharma Manufacturing	
IPQ125	Siegfried	
IPQ126	Siemens Healthcare Diagnostics Inc.	
IPQ127	Sigma Aldrich	
IPQ128	Sigma Aldrich	
IPQ129	Spectrum	
IPQ130	Stepan	
IPQ131	St. Mary's Medical Park Pharmacy	
IPQ132	Sun Pharmaceuticals	

IPQ133	Sun Pharmaceuticals	(b)(4);(b)(7)(E)
IPQ134	Teva Pharmaceuticals	
IPQ135	UCB Manufacturing (formerly Celltech NY)	
IPQ136	Unique Pharmaceuticals	
IPQ137	Varian	
IPQ138	Vintage	
IPQ139	Vintage	
IPQ140	VistaPharm	
IPQ141	Watson	
IPQ142	Watson	
IPQ143	Watson	
IPQ144	Watson	
IPQ145	Watson	
IPQ146	Amneal - Brookhaven	
IPQ147	Amneal - Hauppage	
IPQ148	Cima Brooklyn Park	
IPQ149	Cima Eden Prairie	
IPQ150	Palmetto State Pharmaceuticals	
IPQ151	AmeriSource Ohio	
IPQ152	Sharp Corporation	
IPQ153	Elite	
IPQ154	3M West Water Street	
IPQ155	Bryant Ranch Prepack	
IPQ156	Central Admixture - San Diego	
IPQ157	Central Admixture - Denver	

IPQ158	Boehringer Ingelheim	(b)(4),(b)(7)(E)
IPQ159	Anderson Packaging, Inc	
IPQ160	AAI 1726 North 23rd	
IPQ161	Actavis Mid-Atlantic	
IPQ162	AMRI Rensselear, Inc	
IPQ163	Alaunus Pharmaceutical, Inc	
IPQ164	American Radiolabeled Chemicals	
IPQ165	Bend Research	
IPQ166	Med Shop Total Care	
IPQ167	Core Tech Solutions, Inc.	
IPQ168	Cerovene	
IPQ169	Durect	
IPQ170	Fisher - Bristol, PA	
IPQ171	Jerome Stevens	
IPQ172	Catalent Pharma	
IPQ173	Fisher Pennsylvania	
IPQ174	AAI pharma	
IPQ175	AAI pharma	
IPQ176	Amneal	
IPQ177	Anazao Health	
IPQ178	Aptuit, Inc	
IPQ179	Aveva Drug Delivery (formerly Elan Transdermal)	
IPQ180	ElSohly Laboratories, Inc.	
IPQ181	Formurex, Inc.	
IPQ182	Lannett	

IPQ183	Mylan	(b)(4);(b)(7)(E)
IPQ184	Ortho McNeil Pharmaceutical	
IPQ185	Par	
IPQ186	Par	
IPQ187	PD-RX Pharmaceuticals	
IPQ188	PCCA	
IPQ189	P.F. Laboratories	
IPQ190	PrePak Systems	
IPQ191	Sandoz	
IPQ192	Sovereign	
IPQ193	Tris Pharma, Inc.	
IPQ194	Watson	
IPQ195	Pharmaceuticals International, Inc.	
IPQ196	Lannett	
IPQ197	LTS Lohmann Therapy System Corp	
IPQ198	Mallinckrodt St. Louis	
IPQ199	Nextar	
IPQ200	GE Healthcare	
IPQ201	Bilcare, Inc.	
IPQ202	West-ward	
IPQ203	Rx Pak	

QUOTA APPLICANTS WITH ADVERSE OR DEROGATORY INFORMATION

(b)(4);(b)(7)(E)

The company can conduct business as usual with the expired license until a decision is reached on the registration.

Per consultation with the field office, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact (b)(6);(b)(7)(C) Chief/ODGR at (b)(6);(b)(7)(C)

Memorandum

Subject	Date
Quota Letter Received as of December 16, 2010 (DFN: 630-08.2)	DEC 17 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On December 16, 2010, this section received your e-mail requesting a review of one (1) quota application from a registered manufacturer to determine if there are any pending administrative/legal actions against this applicant and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

USP (10906) (b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject	Date
Quota Letter Received as of December 16, 2010 (DFN: 630-08.2)	DEC 17 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

for Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On December 16, 2010, this section received your e-mail requesting a review of one (1) quota application from a registered manufacturer to determine if there are any pending administrative/legal actions against this applicant and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

USP (10906) (b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

FY 2011 PERFORMANCE BUDGET

DRUG ENFORCEMENT ADMINISTRATION

Congressional Budget Submission

U.S. Department of Justice

To achieve this mission, the DCP does the following:

- Identifies and targets those responsible for the diversion of pharmaceutical controlled substances and chemicals through traditional investigative and cyber crime initiatives; and,
- Supports the DEA DCP registrants with improved technology, including the E-Commerce Initiative.

The following strategies outline DEA's plan to achieve these objectives:

Investigate and prepare for prosecution, violators of chemical and pharmaceutical controlled substances laws at the international, national, State, and local levels while maintaining cooperation, support, and assistance from the regulated industry.

Enforcement Activities

DEA has historically utilized Tactical Diversion Squads (TDS) since the late 1970s. These TDSs allow for the unification of separate and sometimes disparate Federal, State, and local information, authorities, and enforcement programs. They work with State and local (S&L) law enforcement authorities in developing more effective enforcement programs against diversion. TDSs also help coordinate with various judicial districts to maximize the effectiveness of multiple investigations and prosecutions of those involved in the diversion of controlled substances and chemicals.

TDSs investigate suspected violations of the CSA and other appropriate Federal or state statutes pertaining to the diversion of licit pharmaceuticals and chemicals. These unique groups combine the resources of DEA (both Special Agents and Diversion Investigators) with S&L law enforcement agencies in an innovative effort to investigate, disrupt and dismantle those individuals or organizations involved in diversion schemes (e.g., "doctor shoppers," prescriptions forgers, and prevalent retail-level violators). TDSs develop sources of information and disseminate intelligence to appropriate elements for the development of leads and targets. The TDS provides support to a Diversion Group and/or a Diversion Staff where law enforcement authority (LEO) activities are required (e.g., purchase of evidence/purchase of information, conducting surveillance, conducting undercover operations, making arrests, and executing search/seizure warrants).

The realignment of DCP personnel into the new TDSs will be accomplished in phases over several years. Phase 1 will implement a basic infrastructure utilizing existing position authorizations, personnel and funding in FY 2009. A full implementation of Phase 2 will require additional budget authority and fee collections.

Additional functions of the DCP include:

- Operational support activities essential to the operation of the above priorities including registration and regulatory support, Diversion Investigator recruitment, training, and drug/chemical surveys; and,

C.	**Item Name:**	**Diversion Control Program Enforcement and Regulatory Support**
Budget Decision Unit(s):		Diversion Control Fee Account
Strategic Goal & Objective:		Goal II; Objective 2.4
Organization Program:		Office of Diversion Control Special Operation Division
Program Increase:		Positions 174 Agents 62 FTE 87 Dollars $33,508,000

Description of Item

DEA requests $33,508,000 (including $4,314,000 in non-personnel funding) and 174 positions (including 62 agents) to address staffing shortfalls at DEA headquarters, Special Operations Divisions (SOD), and in domestic field offices to support. The DOJ Office of Inspector General's (OIG) 2006 report "Follow up Review of the Drug Enforcement Administration's Efforts to Control the Diversion of Pharmaceuticals" found that the Diversion Control Program needed to increase law enforcement support to assist the program in performing inherently law enforcement activities. In order to satisfy this requirement, the Diversion Control Program increased its Special Agent authorization by adding 23 new Special Agents in FY 2006; moving 29 existing direct-funded Special Agents to the fee account in FY 2006; and converting 108 vacant Diversion Investigator positions to Special Agents positions in FY 2007. While meeting immediate enforcement needs, the conversion of Diversion Investigator positions to Special Agents has significantly depleted available resources to conduct regulatory control functions.

DEA is working to fulfill both the regulatory control and enforcement aspects of the Diversion Control Program in FY 2011 and beyond. This approach will help the Diversion Control Program meet immediate and future needs regarding both regulatory control and enforcement activities and ensure the appropriate mix of Diversion Investigators, Special Agents, and support personnel.

Justification

Regulatory Activities
DEA requests $3,384,000 for 23 diversion investigator positions to address existing staffing shortfalls in the regulatory program and to increase the focus on regulatory oversight functions. This includes the modification of chemical and regulatory work plans to increase the frequency of scheduled investigations and to broaden the pool of registrants that are subject to scheduled regulatory investigations. Increasing the frequency of inspections/investigations will ultimately help industry comply with the Controlled Substances Act (CSA) and its implementing regulations, and more easily identify those who are potential avenues for diversion. The last significant increase to Diversion Investigator positions was accomplished in the FY 2004 budget;

however, 108 vacant Diversion Investigator positions were converted to Special Agent positions because of immediate law enforcement requirements identified in the 2006 OIG report. Thus, the loss of Diversion Investigator positions, combined with the need to step up an aggressive regulatory control program requires replenishment and an increase in Diversion Investigator resources. DEA's goal as described will be implemented over several years as positions are authorized, collections support funding requests, and positions are staffed.

In addition, the new work plan modification will require that all newly-approved controlled substance and chemical registrants will be subject to a scheduled investigation within one year of approval and issuance of a DEA registration. Thus, this will require the deployment of additional Diversion Investigators.

Enforcement Activities
DEA requests $23,560,000 (including $3,939,000 in non-personnel funding) and 97 positions (including 60 special agents and 37 diversion investigators) for Tactical Diversion Squads (TDSs). TDSs combine Special Agents, Diversion Investigators, and State and Local Task Force Officer (S&L) resources to provide law enforcement support to DEA's Diversion Control Program. DEA is currently using existing Special Agent and Diversion Investigator positions to organize TDSs in each domestic field division. DEA requests 60 new Special Agents and 37 new Diversion Investigator positions to solidify existing TDSs where S&L personnel are limited and to establish new TDSs in areas of significant pharmaceutical diversion; 3 new Telecommunications Specialist (ITS) positions to support the Office of Investigative Technology's Diversion Internet Intercept Program; and 5 new Attorney positions to support case development including Orders to Show Cause and Immediate Suspensions. This request also includes $3,175,000 for overtime and other overhead costs for 64 new State and local Task Force Officers (TFO), and $264,000 for 8 new contract clerical personnel for TDSs.

TDSs allow for the unification of separate and sometimes disparate Federal, State, and local information, authorities, and enforcement programs. They work with S&L law enforcement authorities in developing more effective enforcement programs against diversion. TDSs also help coordinate with various judicial districts to maximize the effectiveness of multiple investigations and prosecutions of those involved in the diversion of controlled substances and chemicals.

TDSs investigate suspected violations of the CSA and other appropriate Federal or state statutes pertaining to the diversion of licit pharmaceuticals and chemicals. These unique groups combine the resources of DEA (both Special Agents and Diversion Investigators) with S&L law enforcement agencies in an innovative effort to investigate, disrupt and dismantle those individuals or organizations involved in diversion schemes (e.g., "doctor shoppers," prescriptions forgers, and prevalent retail-level violators). TDSs develop sources of information and disseminate intelligence to appropriate elements for the development of leads and targets. The TDSs provides support to Diversion Groups and staff where law enforcement authority activities are required (e.g., purchase of evidence/purchase of information, conducting surveillance, conducting undercover operations, making arrests, and executing search/seizure warrants).